Drug name - Turalio

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8404700 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(5 years from now)

US8722702 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(5 years from now)

US9169250 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(5 years from now)

US7893075 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Oct, 2028

(6 years from now)

US9802932 DAIICHI SANKYO INC Solid forms of a compound modulating kinases
May, 2036

(13 years from now)

US10730876 DAIICHI SANKYO INC Synthesis of a compound that modulates kinases
May, 2036

(13 years from now)

CN107531706A DAIICHI SANKYO INC Synthesis Of 1H-Pyrrolo[2,3-B]Pyridine Ramification Of Regulated Kinase
May, 2021

(1 year, 4 months ago)

CN103497188A DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity And Uses Therefor
Nov, 2027

(5 years from now)

CN101605787A DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity And Uses Therefore
Nov, 2027

(5 years from now)

CN103497188B DAIICHI SANKYO INC Adjusting C-Fms And/Or C-Kit Active Compound And Application Thereof
Nov, 2027

(5 years from now)

CN101605787B DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity And Uses Therefor
Nov, 2027

(5 years from now)

CN107548394B DAIICHI SANKYO INC A Solid Form Of The Compound For Modulating Kinase
May, 2036

(13 years from now)

CN107548394A DAIICHI SANKYO INC Solid Forms Of The Kinase Modulating Compound
May, 2036

(13 years from now)

IN271905B DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity
Nov, 2027

(5 years from now)

IN200901879P2 DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity And Uses Therefor
Nov, 2027

(5 years from now)

EP2086972A2 DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity And Uses Therefor
Nov, 2027

(5 years from now)

EP2086972B1 DAIICHI SANKYO INC Compounds Modulating C-Fms And/Or C-Kit Activity And Uses Therefor
Nov, 2027

(5 years from now)

EP3581573A1 DAIICHI SANKYO INC Synthesis Of A Compound That Modulates Kinases
May, 2036

(13 years from now)

EP3292122B1 DAIICHI SANKYO INC Synthesis Of 1H-Pyrrolo[2,3-B]Pyridin Derivatives That Modulate Kinases
May, 2036

(13 years from now)

EP3292123B1 DAIICHI SANKYO INC Solid Forms Of A Compound Modulating Kinases
May, 2036

(13 years from now)

EP3581573B1 DAIICHI SANKYO INC Synthesis Of A Compound That Modulates Kinases
May, 2036

(13 years from now)

EP3292123A1 DAIICHI SANKYO INC Solid Forms Of A Compound Modulating Kinases
May, 2036

(13 years from now)

EP3292122A1 DAIICHI SANKYO INC Synthesis Of 1H-Pyrrolo[2,3-B]Pyridin Derivatives That Modulate Kinases
May, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461169 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity Apr, 2028

(5 years from now)

US9358235 DAIICHI SANKYO INC Kinase modulation, and indications therefor Jun, 2033

(10 years from now)

US10189833 DAIICHI SANKYO INC Solid forms of a compound modulating kinases May, 2036

(13 years from now)

US10435404 DAIICHI SANKYO INC Formulations of a compound modulating kinases Jul, 2038

(15 years from now)

US10941142 DAIICHI SANKYO INC Formulations of a compound modulating kinases Jul, 2038

(15 years from now)

US10961240 DAIICHI SANKYO INC Formulations of a compound modulating kinases Jul, 2038

(15 years from now)

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.